vTv Therapeutics Inc (VTVT)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$25.55-5.93%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge vTv Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-1.107
Annual ending 2026-12-31
Revenue	—	36.87M
EPS	—	-1.208
Annual ending 2027-12-31
Revenue	—	800,000
EPS	—	-4.147

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Capital raising via ATM program	It aims to raise capital through its ATM program.	Intact	ATM program not expanded or capital raising fails in 2026	ATM expanded to full amount May 13, 2026 prospectus supplement increased ATM program shares to the full amount provided for under the program. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Net income improvement through operational efficiency	Net income rose from -$7.1M to $24.1M.	Intact	net income falls below -$5M in any quarter next year	Net income: $-13.054M FY2026-Q2; GAAP. Published target: net income > $20M in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 6, 2026-13,054,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 124252ef-837b-4c88-934e-86c2463003da. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue growth from strategic partnerships	A primary condition in vTv Therapeutics Inc's published investment case. The stated target is >= $36.84M revenue in 2026-Q1.	Under Pressure	revenue falls below $20M in any quarter next year	Revenue: $0 FY2026-Q2; GAAP. Published target: >= $36.84M revenue in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 6, 20260 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-4.15

Unavailable → $-4.15 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$1,000,000	4 / 6
2026-07-25	Unavailable	$1,000,000	4 / 6
2026-07-26	Unavailable	$1,000,000	4 / 6
2026-07-27	Unavailable	$1,000,000	4 / 6
2026-07-28	$-3.89	$0	6 / 6
2026-07-29	Unavailable	$1,000,000	4 / 6
2026-07-30	Unavailable	$1,000,000	4 / 6
2026-07-31	Unavailable	$1,000,000	4 / 6
2026-08-01	Unavailable	$1,000,000	4 / 6
2026-08-02	Unavailable	$1,000,000	4 / 6
2026-08-03	Unavailable	$1,000,000	4 / 6
2026-08-04	$-3.89	$0	6 / 6
2026-08-05	$-3.89	$0	6 / 5
2026-08-06	$-3.89	$0	6 / 5
2026-08-08	Unavailable	$1,000,000	4 / 5
2026-08-09	$-4.07	$0	6 / 5
2026-08-10	$-4.07	$0	6 / 5
2026-08-12	Unavailable	$1,000,000	4 / 5
2026-08-13	Unavailable	$1,000,000	4 / 5
2026-08-14	Unavailable	$1,000,000	4 / 5
2026-08-15	Unavailable	$1,000,000	4 / 5
2026-08-16	Unavailable	$1,000,000	4 / 5
2026-08-17	Unavailable	$1,000,000	4 / 5
2026-08-18	Unavailable	$1,000,000	4 / 5
2026-08-19	Unavailable	$1,000,000	4 / 5
2026-08-20	Unavailable	$800,000	4 / 5
2026-08-21	Unavailable	$800,000	4 / 5
2026-08-22	Unavailable	$800,000	4 / 5
2026-08-23	Unavailable	$1,000,000	4 / 5
2026-08-24	Unavailable	$1,000,000	4 / 5
2026-08-25	Unavailable	$1,000,000	4 / 5
2026-08-26	Unavailable	$1,000,000	4 / 5
2026-08-27	Unavailable	$1,000,000	4 / 5
2026-08-28	Unavailable	$1,000,000	4 / 5
2026-08-29	Unavailable	$1,000,000	4 / 5
2026-08-30	Unavailable	$1,000,000	4 / 5
2026-08-31	Unavailable	$1,000,000	4 / 5
2026-09-01	Unavailable	$1,000,000	4 / 5
2026-09-02	Unavailable	$1,000,000	4 / 5
2026-09-03	$-4.43	$800,000	5 / 5
2026-09-04	$-4.43	$800,000	5 / 6
2026-09-05	$-4.43	$800,000	5 / 6
2026-09-06	$-4.43	$800,000	5 / 6
2026-09-07	$-4.43	$800,000	5 / 6
2026-09-08	$-4.43	$800,000	5 / 6
2026-09-09	$-4.43	$800,000	5 / 6
2026-09-10	$-4.43	$800,000	5 / 6
2026-09-11	$-4.43	$800,000	5 / 6
2026-09-12	$-4.43	$800,000	5 / 6
2026-09-13	$-4.43	$800,000	5 / 6
2026-09-14	$-4.43	$800,000	5 / 6
2026-09-15	$-4.43	$800,000	5 / 6
2026-09-16	$-4.43	$800,000	5 / 6
2026-09-17	$-4.43	$800,000	5 / 6
2026-09-18	$-4.43	$800,000	5 / 6
2026-09-19	$-4.43	$800,000	5 / 6
2026-09-20	$-4.43	$800,000	5 / 6
2026-09-21	$-4.43	$800,000	5 / 6
2026-09-22	$-4.43	$800,000	5 / 6
2026-09-23	$-4.43	$800,000	5 / 6
2026-09-24	Unavailable	$800,000	4 / 5
2026-09-25	Unavailable	$800,000	4 / 5
2026-09-26	Unavailable	$800,000	4 / 5
2026-09-27	Unavailable	$800,000	4 / 5
2026-09-28	Unavailable	$800,000	4 / 5
2026-09-29	Unavailable	$800,000	4 / 5
2026-09-30	Unavailable	$800,000	4 / 5
2026-10-01	Unavailable	$800,000	4 / 5
2026-10-02	Unavailable	$800,000	4 / 5
2026-10-03	Unavailable	$800,000	4 / 5
2026-10-04	Unavailable	$800,000	4 / 5
2026-10-05	Unavailable	$800,000	4 / 5
2026-10-06	Unavailable	$800,000	4 / 5
2026-10-07	Unavailable	$800,000	4 / 5
2026-10-08	Unavailable	$800,000	4 / 5
2026-10-09	Unavailable	$800,000	4 / 5
2026-10-10	Unavailable	$800,000	4 / 5
2026-10-11	Unavailable	$800,000	4 / 5
2026-10-12	Unavailable	$800,000	4 / 5
2026-10-13	Unavailable	$800,000	4 / 5
2026-10-14	Unavailable	$800,000	4 / 5
2026-10-15	Unavailable	$800,000	4 / 5
2026-10-16	$-4.15	$800,000	5 / 6
2026-10-17	$-4.15	$800,000	5 / 6
2026-10-18	$-4.15	$800,000	5 / 6
2026-10-19	$-4.15	$800,000	5 / 6
2026-10-20	$-4.15	$800,000	5 / 6
2026-10-21	$-4.15	$800,000	5 / 6
2026-10-22	$-4.15	$800,000	5 / 6
2026-10-23	$-4.15	$800,000	5 / 6
2026-10-24	$-4.15	$800,000	5 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	6	0	0
2026-06-01	6	0	0
2026-07-01	6	0	0
2026-08-01	6	0	0
2026-09-01	7	0	0
2026-10-01	7	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Net income improvement through operational efficiencyNet income: $-13.054M
Revenue growth from strategic partnershipsPublished status: Under Pressure

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.7%Typical daily move · historical

Downside history

-40.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

vTv Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk clinical-stage healthcare company, where the long-term case depends on trial progress rather than a mature earnings base. The thesis is currently intact, with management execution mixed and earnings quality fragile.

What's priced into vTv Therapeutics Inc

The evidence snapshot provides no valuation or market-expectations data, so whether the shares look cheap, fair, or expensive and what expectations are priced in cannot be assessed. The recent earnings miss and the preceding earnings beat show that results have been erratic.

What the fundamentals likely do

Recent financial performance is described as strong relative to the industry, but the latest recorded event was an earnings miss, and near-term miss risk is elevated. Management expects to complete Phase 3 CATT1 enrollment by Q3 2026 and says available cash can fund operations through the expected data readout, though cash declined in Q2.

What vTv Therapeutics Inc hinges on

The multi-year case depends on progress toward CATT1 enrollment and a data readout, alongside maintaining enough cash to reach that milestone. A guidance cut or weaker jobs data would add near-term pressure, while stronger results and guidance from healthcare bellwethers could support sector momentum.